Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparing the Effectiveness and Costs of Bevacizumab to Ranibizumab in Patients With Retinal Vein Occlusions (BRVO) (BRVO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01635803
Recruitment Status : Unknown
Verified June 2015 by Prof. dr. R.O. Schlingemann, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA).
Recruitment status was:  Recruiting
First Posted : July 10, 2012
Last Update Posted : July 1, 2015
Sponsor:
Collaborators:
Leiden University Medical Center
Free University Medical Center
Erasmus Medical Center
Radboud University
UMC Utrecht
University Medical Center Groningen
Information provided by (Responsible Party):
Prof. dr. R.O. Schlingemann, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Brief Summary:
The primary objective is to demonstrate the non-inferiority of bevacizumab in the treatment of patients with macular edema secondary to a retinal vein occlusion (branch or central) as determined by the change in best-corrected visual acuity in the study eye from baseline to month 6.

Condition or disease Intervention/treatment Phase
Retinal Vein Occlusion Drug: Bevacizumab Drug: Ranibizumab Phase 2 Phase 3

Detailed Description:

Objective: to compare the effectiveness and costs of 1.25 mg bevacizumab to 0.5 mg ranibizumab, given as monthly intravitreal injections during 6 months.

Study Design: This will be a randomized, controlled, double masked, clinical trial in 296 patients in 7 academic trial centres in The Netherlands.

Study population: patients older than 18 years of age with macular edema secondary to a retinal vein occlusion and a best corrected visual acuity (BCVA) score between 78 and 20 letters in the study eye.

Outcomes: The primary outcome measure will be the change in BCVA in the study eye from baseline to month 6.

Secondary outcomes will be amongst others the proportion of patients with a gain of 15 letters or more and/or a BCVA of 20/40 or more at 6 months and the costs per quality adjusted life-year of the two treatments

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 296 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Comparing the Effectiveness and Costs of Bevacizumab to Ranibizumab in Patients With Retinal Vein Occlusions (The BRVO Study)
Study Start Date : June 2012
Estimated Primary Completion Date : June 2016

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Ranibizumab
Monthly injections with ranibizumab during 6 months
Drug: Ranibizumab
0.5mg ranibizumab administered by monthly interval for six months (6 injections).
Other Name: Lucentis

Active Comparator: Bevacizumab
Monthly injections with bevacizumab during 6 months
Drug: Bevacizumab
1.25 mg bevacizumab administered by monthly interval for six months (6 injections).
Other Name: Avastin




Primary Outcome Measures :
  1. Best corrected visual acuity [ Time Frame: 6 months ]
    The primary outcome is the change in best-corrected visual acuitiy (BCVA) in the study eye from baseline to month 6 assessed with EDTRS-like VA charts at an initial distance of four meter.


Secondary Outcome Measures :
  1. Proportion of patients with a gain or loss of 15 letters or more [ Time Frame: 6 months ]
    The proportion of patients with a gain or loss of 15 letters or more at 6 months compared to baseline BCVA

  2. Change in leakage on fluorescein angiography [ Time Frame: 6 months ]
    The change in leakage on fluorescein angiography at the 6 month exit visit compared to baseline

  3. Change in foveal thickness by optical coherence tomography [ Time Frame: 6 months ]
    The change in foveal thickness (central area thickness) by optical coherence tomography at 6 months compared to baseline

  4. The number of adverse events [ Time Frame: 6 months ]
    The number of adverse events that occurred in the time frame of 6 months and a classification of the type of adverse events

  5. Costs per quality adjusted life-year of the two treatments [ Time Frame: 6 months ]
    The costs per quality adjusted life-year of the two treatments, results will be based on the use of standardized health questionnaires (EQ5D or HUI3)

  6. The proportion of patients with a BCVA of 20/40 or more [ Time Frame: 6 months ]
    The proportion of patients with a BCVA of 20/40 or more at 6 months compared to baseline BCVA



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female patients > 18 years of age with vision loss due to foveal center-involved ME secondary to branch or central retinal vein occlusion diagnosed within 6 months before study initiation, who have signed an informed consent;
  • BCVA equal or more than 24 and less or equal to 78 letters in the study eye at screening using ETDRS- like visual acuity testing charts at a testing distance of 4 meters
  • Mean central subfield thickness more than 275 micron on 2 OCT measurements.

Exclusion Criteria:

  1. Women of child-bearing potential.
  2. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive serum pregnancy test (human chorionic gonadotropin > 5 mIU/ml);
  3. Inability to comply with study procedures;
  4. Active intraocular inflammation in either eye at enrolment;
  5. Any active infection in either eye at the time of enrolment;
  6. History of uveitis in either eye at any time;
  7. Structural damage within 600 micron of the center of the macula in the study eye likely to preclude improvement in visual acuity following in the resolution of macular edema, including atrophy of the retinal pigment epithelium, subretinal fibrosis, laser scar(s), epiretinal membrane involving fovea or organized hard exudate plaques;
  8. Uncontrolled (neovascular) glaucoma in the study eye at screening. (IOP > 24 mmHg on medication or according to investigator's judgment);
  9. Evidence of vitreomacular traction in the study eye;
  10. Patients who are monocular or have a Snellen VA in the non-study eye ≤ 1/300 at visit 1;
  11. Any intraocular surgery in the study eye within 3 months prior to randomization;
  12. Planned medical or surgical intervention during the 6-months study period;
  13. Panretinal laser photocoagulation in the study eye within 3 months prior to or during the study;
  14. Focal/grid laser photocoagulation in the study eye 3 months prior to study entry;
  15. Treatment with anti-angiogenic drugs in the study eye within 3 months prior to randomization;
  16. Use of other investigational drugs at the time of enrolment, or within 3 months or 5 half-lives from enrolment, whichever is longer;
  17. History of intravitreal corticosteroids in study eye within 4 months prior to randomization;
  18. Ocular conditions in the study eye that require chronic concomitant therapy with topical ocular or systemically administered corticosteroids;
  19. History of stroke or transient ischemic attack (TIA) within 6 months prior to enrolment;
  20. History of myocardial infarction within 3 months prior to randomization;
  21. Current use of or likely need for systemic medications known to be toxic to the lens, retina or optic nerve, including deferoxamine, chloroquine/hydroxychloroquine (Plaquenil), tamoxifen, phenothiazines and ethambutol;
  22. Known hypersensitivity to fluorescein, bevacizumab or ranibizumab or any component thereof or drugs of similar chemical classes;
  23. Any type of advanced, severe or unstable disease or its treatment, that may interfere with primary and/or secondary variable evaluations including any medical condition that could be expected to progress, recur, or change to such an extend that it may bias the assessment of the clinical status of the patient to a significant degree or put the patient at special risk;
  24. Ocular disorders in the study eye that may confound interpretation of study results, compromise visual acuity or require medical or surgical intervention during the 6 month study period, including cataract, retinal vascular occlusion, retinal detachment, macular hole, or choroidal neovascularisation of any cause (e.g., AMD, ocular histoplasmosis, or pathologic myopia);
  25. Prior episode of RVO;
  26. Evidence on examination of sight-threatening diabetic retinopathy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01635803


Contacts
Layout table for location contacts
Contact: Reinier O Schlingemann, PhD, MD +31 20 5663682 r.schlingemann@amc.uva.nl
Contact: Monique -- Wezel +31 205663616 m.wezel@amc.uva.nl

Locations
Layout table for location information
Netherlands
Academic Medical Center, Dept. Ophthalmology Recruiting
Amsterdam, Netherlands, 1105 AZ
Contact: Reinier O Schlingemann, MD, PhD    +31 205663682    r.schlingemann@amc.uva.nl   
Contact: Monique Wezel    +31 205663616    m.wezel@amc.uva.nl   
Principal Investigator: Reinier O Schlingemann, MD, PhD         
Sponsors and Collaborators
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Leiden University Medical Center
Free University Medical Center
Erasmus Medical Center
Radboud University
UMC Utrecht
University Medical Center Groningen
Investigators
Layout table for investigator information
Principal Investigator: Reinier O Schlingemann, MD, PhD Academic Medical Center, Dept. Ophthalmology, Room A2-122, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
Layout table for additonal information
Responsible Party: Prof. dr. R.O. Schlingemann, Clinical Professor, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
ClinicalTrials.gov Identifier: NCT01635803    
Other Study ID Numbers: NL35869.018.11
First Posted: July 10, 2012    Key Record Dates
Last Update Posted: July 1, 2015
Last Verified: June 2015
Keywords provided by Prof. dr. R.O. Schlingemann, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA):
bevacizumab
ranibizumab
retinal vein occlusions
randomized clinical trial
Macular edema
Additional relevant MeSH terms:
Layout table for MeSH terms
Retinal Vein Occlusion
Retinal Diseases
Eye Diseases
Venous Thrombosis
Thrombosis
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Bevacizumab
Ranibizumab
Antineoplastic Agents, Immunological
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors